Eptifibatide Continues to be Successful as an Antiplatelet Agent

Eptifibatide Continues to be Successful as an Antiplatelet Agent

Eptifibatide, CAS# 188627-80-7, is an antiplatelet agent. Also offered from LGM Pharma as a TEVA API (TAPI) product for compounding purposes, eptifibatide is also known by the brand name Integrilin, which is marketed by Merck. With Merck’s patent for Integrilin due to expire on November 11, 2014, and an additional patent revision due to expire on May 5, 2015, this powerful drug is set to be a generic blockbuster.

Eptifibatide angioplastyEptifibatide is effective as it keeps the platelets in your blood from clotting or coagulating, which prevents unwanted blood clots from forming. This is especially important for treating patients with certain heart or blood vessel conditions. In addition, patients who are undergoing an angioplasty, or a procedure to open blocked arteries, are often dosed with eptifibatide to prevent blood clots from forming after surgery. As an injectable medication, eptifibatide is administered through an I.V. in a hospital or ambulatory care setting. Often times the injection is dispensed around the clock for up to four days in a row. Eptifibatide may also be given throughout an angioplasty procedure, and up to 24 hours following. Aspirin may sometimes be dispensed as an adjunct therapy to eptifibatide, under a physician’s supervision only. Because eptifibatide keeps your blood from clotting, it can also make it easier for patients to bleed, even from a minor cut. It is imperative that any patient who receives eptifibatide and experiences uncontrolled bleeding to stop taking this drug and seek medical assistance. Side effects of eptifibatide may include nausea, stomach upset and bleeding around the I.V. injection point. The initial dose for patients with angina pectoris, acute coronary syndrome, myocardial infarction or percutaneous coronary intervention is 180 mcg/kg, to be administered intravenously as soon as possible following the diagnosis.

eptifibatideResearch teams are prepared for a study to be halted due to safety and tolerability issues, but they are typically not prepared for a study to cease due to success. This was the case for the ESPRIT study, which involved 2,400 patients undergoing coronary intervention and dosed with eptifibatide (Integrilin). An interim analysis of 1,758 patients showed a significant reduction for the combined incidence of death or myocardial infarction with patients who received eptifibatide versus those who received a placebo. This reduction was substantial, accounting for over 50 percent of patients at a 30 day interim analysis, thus halting the need for further investigation. In addition to this outstanding discovery, many patients displayed positive results from their injection of eptifibatide after only 48 hours. The reliability and efficacy of eptifibatide has been demonstrated, paving the way for generic options of this phenomenal drug. LGM Pharma is a provider of the API and TEVA API of eptifibatide for research and development, and offers complete support to clients throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service